Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Company Description

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China.

It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors.

The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which has completed Phase IV clinical trial; and Aminolevulinic acid–CIN, which has completed Phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid–AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid–acne, which is in phase II clinical trials for Acne; Aminolevulinic acid–gliomas for surgical visualization of gliomas; Aminolevulinic acid–bladder for surgical visualization of bladder cancer; and Aminolevulinic acid–breast for surgical visualization of breast cancer.

In addition, it offers Osmotic pump technology platform drugs, which includes controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson’s disease; and Obeticholic acid for the treatment of hepatobiliary/autoimmune diseases.

Further, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software.

Additionally, the company engages in the technology development, transfer, consulting, and promotion activities.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. was founded in 1996 and is based in Shanghai, the People's Republic of China.